Celgene Overview

  • Founded
  • 1986
Founded
  • Status
  • Acquired/​Merged
  • Employees
  • 5,348
Employees
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $80.3B
Latest Deal Amount

Celgene General Information

Description

Celgene is a biopharmaceutical firm that discovers, develops, and markets therapeutics for the treatment of cancer and immunological diseases. Celgene markets Thalomid and Pomalyst to treat multiple myeloma and Revlimid, a less toxic thalidomide derivative, to treat myelodysplastic syndromes, multiple myeloma, and mantle cell lymphoma. Acquisitions have brought MDS drug Vidaza, T-cell lymphoma drug Istodax, and cancer drug Abraxane. The firm's first immunology drug, Otezla, was approved in the U.S. in 2014. Recent acquisitions of Juno and Impact bring additional drugs for Celgene's blood cancer pipeline.

Contact Information

Website
www.celgene.com
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Parent Company
Primary Office
  • 86 Morris Avenue
  • Summit, NJ 07901
  • United States
+1 (908) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Celgene Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Merger/Acquisition 20-Nov-2019 $80.3B 000.00 000.00 Completed Profitable
3. PIPE 000.00 Completed Profitable
2. IPO 28-Jul-1987 $12.7M $12.7M Completed Generating Revenue
1. Early Stage VC 01-Jan-1986 Completed Generating Revenue
To view Celgene’s complete valuation and funding history, request access »

Celgene Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Celgene is a biopharmaceutical firm that discovers, develops, and markets therapeutics for the treatment of cancer and i
Biotechnology
Summit, NJ
5,348 As of 2020
000.00
00.00 0000-00-00
000000&0 000.00

0000000

, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut
0000 000000000
Bothell, WA
0000 As of 0000
00.000
000000000 00.000

00000000

quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure
000000000000000
Tarrytown, NY
0000 As of 0000
00000
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Celgene Competitors (20)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Seattle Genetics Formerly VC-backed Bothell, WA 0000 00.000 000000000 00.000
000000000 00000000 Formerly VC-backed Tarrytown, NY 0000 00000 00000000000 00000
000000 00000000 Formerly VC-backed Foster City, CA 00000 00.000 000000&0
000000000 Formerly VC-backed Exton, PA 000 0000 000000&0 0000
000000 Formerly VC-backed Cambridge, MA 0000 000.00 00000000000 000.00
You’re viewing 5 of 20 competitors. Get the full list »

Celgene Executive Team (63)

Name Title Board Seat Contact Info
Robert Hugin Chief Executive Officer & Executive Chairman
Anne Bucci Senior Executive Administrative Assistant
Björn Hellström Nordic Director CAR T
John Chardonnens TitleDirector, IT Site Lead and Business Partner
Laure Escoubet Ph.D Executive
You’re viewing 5 of 63 executive team members. Get the full list »

Celgene Board Members (28)

Name Representing Role Since
Carrie Cox Self Board Member 000 0000
Ernest Mario Ph.D Self Board Member 000 0000
Gilla Kaplan Self Board Member 000 0000
Hans Bishop Self Board Member 000 0000
James Loughlin Self Board Member 000 0000
You’re viewing 5 of 28 board members. Get the full list »

Celgene Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Celgene Former Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Asseily Ventures Venture Capital Minority 000 0000 000000 0
BB Biotech Asset Manager Minority 000 0000 000000 0
CHL Medical Partners Venture Capital Minority 000 0000 000000 0
Edelson Technology Partners Venture Capital Minority 000 0000 000000 0
Ridgeback Capital Other Minority 000 0000 000000 0
To view Celgene’s complete investors history, request access »

Celgene Investments & Acquisitions (126)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000 0000000000 07-Jan-2020 00000 00000 00 0000 Decision/Risk Analysis
0000000 20-Dec-2019 00000 00000 00 000.00 Drug Discovery
000000 00000000000 15-Oct-2019 00000 00000 00 000.00 Drug Discovery 00000 000000000
0000000 11-Sep-2019 00000 00000 00 000.00 Drug Discovery
RAPT Therapeutics 18-Jun-2019 Later Stage VC 0000 Drug Discovery
You’re viewing 5 of 126 investments and acquisitions. Get the full list »

Celgene Subsidiaries (5)

Company Name Industry Location Founded
EngMab Biotechnology Pfaffikon, Switzerland 2013
000000000 00000000 Therapeutic Devices San Francisco, CA 0000
00000000 000000000 Drug Discovery Boston, MA 0000
00000000 000000000 Pharmaceuticals Summit, NJ 0000
0000000000000 Diagnostic Equipment Rockville, MD 0000
To view Celgene’s complete subsidiaries history, request access »

Celgene Exits (53)

Company Name Exit Date Exit Type Exit Size Status Buyers
0000000 20-Dec-2019 00000 00000 00 000.00 Completed
  • 16 buyers
0000 000000000000 18-Jun-2019 00000 00000 00 0000 Completed
  • 6 buyers
00000000000 13-Mar-2019 00000 00000 00 0000 Completed
  • 2 buyers
0000000000 0000000 05-Mar-2019 00000 00000 00 000.00 Completed
  • 3 buyers
Silverback Therapeutics 19-Sep-2018 Early Stage VC 000.00 Completed
  • 3 buyers
You’re viewing 5 of 53 exits. Get the full list »